Baum Charles M
SEC-identified person · CIK 1579824 Identifier-verified
Public-company roles (from insider filings)
| Company | Capacity as filed | Filings |
|---|---|---|
| Acrivon Therapeutics, Inc. ACRV | Director | filed 2023 - 2026 |
| PMV Pharmaceuticals, Inc. PMVP | Director | filed 2021 - 2026 |
| Poseida Therapeutics, Inc. PSTX | Director | filed 2022 - 2025 |
| Mirati Therapeutics, Inc. mrtx | Director · President,Founder,Head of R&D | filed 2013 - 2024 |
| Immunomedics INC IMMU | Director | filed 2019 - 2020 |
| Tango Therapeutics, Inc. TNGX | Director | filed 2020 - 2020 |
| Array Biopharma INC ARRY | Director | filed 2014 - 2019 |
All roles under one Commission-assigned identifier - the same person by the SEC's own record, not by name matching. From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.